A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease

• Published in: The New England journal of medicine Vol. 337; no. 7; pp. 447 - 452
• Main Authors: Cohen, Marc, Demers, Christine, Gurfinkel, Enrique P, Turpie, Alexander G.G, Fromell, Gregg J, Goodman, Shaun, Langer, Anatoly, Califf, Robert M, Fox, Keith A.A, Premmereur, Jerome, Bigonzi, Frederique, Stephens, Jim, Weatherley, Beth
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 14.08.1997
• Subjects: Analgesics; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Cardiovascular disease; Drug therapy; Medical sciences; Pharmacology. Drug treatments; Human; Treatment efficiency; Coronary artery; Cardiovascular disease; Low molecular weight heparin; Anticoagulant; Coronary heart disease; Fractionated dose; Incidence; Chemotherapy; Double blind study; Complication; Comparative study
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199708143370702

Antithrombotic therapy consisting of the intravenous infusion of unfractionated heparin plus oral aspirin represents the current standard of care for patients hospitalized with unstable angina or non–Q-wave myocardial infarction. 1 – 6 However, this treatment has a substantial failure rate, probably because of the unpredictable anticoagulant response to standard unfractionated heparin, 7 as well as its neutralization by protein binding and activated platelets, 8 , 9 and rebound clinical events that follow the discontinuation of unfractionated heparin. 10 The low-molecular-weight heparins have several potential advantages over unfractionated heparin. They have a more predictable anticoagulant effect with a higher ratio of anti–factor Xa to anti–factor IIa, 11 require . . .